Terms: = Endocrine gland cancer AND LCP1, CP64, 3936, ENSG00000136167, FLJ39956, DKFZp781A23186, L-PLASTIN, FLJ25423, P13796, FLJ26114, PLS2, LC64P
9 results:
1. Further delineation of the NTHL1 associated syndrome: A report from the French Oncogenetic Consortium.
Boulouard F; Kasper E; Buisine MP; Lienard G; Vasseur S; Manase S; Bahuau M; Barouk Simonet E; Bubien V; Coulet F; Cusin V; Dhooge M; Golmard L; Goussot V; Hamzaoui N; Lacaze E; Lejeune S; Mauillon J; Beaumont MP; Pinson S; Tlemsani C; Toulas C; Rey JM; Uhrhammer N; Bougeard G; Frebourg T; Houdayer C; Baert-Desurmont S
Clin Genet; 2021 May; 99(5):662-672. PubMed ID: 33454955
[TBL] [Abstract] [Full Text] [Related]
2. Proteomic Comparison of Malignant Human Germ Cell Tumor Cell Lines.
Bremmer F; Bohnenberger H; Küffer S; Oellerich T; Serve H; Urlaub H; Strauss A; Maatoug Y; Behnes CL; Oing C; Radzun HJ; Ströbel P; Balabanov S; Honecker F
Dis Markers; 2019; 2019():8298524. PubMed ID: 31565104
[TBL] [Abstract] [Full Text] [Related]
3. Significance of biochemical parameters in differentiating uniglandular from multiglandular disease and limiting use of intraoperative parathormone assay.
Thakur A; Sebag F; Slotema E; Ippolito G; Taïeb D; Henry JF
World J Surg; 2009 Jun; 33(6):1219-23. PubMed ID: 19363691
[TBL] [Abstract] [Full Text] [Related]
4. Proteomic exploitation on prothymosin alpha-induced mononuclear cell activation.
Skopeliti M; Kratzer U; Altenberend F; Panayotou G; Kalbacher H; Stevanovic S; Voelter W; Tsitsilonis OE
Proteomics; 2007 Jun; 7(11):1814-24. PubMed ID: 17474146
[TBL] [Abstract] [Full Text] [Related]
5. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
Gallardo M; Silva A; Rubio L; Alvarez C; Torrealba C; Salinas M; Tapia T; Faundez P; Palma L; Riccio ME; Paredes H; Rodriguez M; Cruz A; Rousseau C; King MC; Camus M; Alvarez M; Carvallo P
Breast Cancer Res Treat; 2006 Jan; 95(1):81-7. PubMed ID: 16261400
[TBL] [Abstract] [Full Text] [Related]
6. Recombinant adenoviral vector containing tumor-specific l-plastin promoter fused to cytosine deaminase gene as a transcription unit: generation and functional test.
Chung I; Deisseroth AB
Arch Pharm Res; 2004 Jun; 27(6):633-9. PubMed ID: 15283466
[TBL] [Abstract] [Full Text] [Related]
7. Cytotoxic effect of replication-competent adenoviral vectors carrying l-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
Akbulut H; Zhang L; Tang Y; Deisseroth A
Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
[TBL] [Abstract] [Full Text] [Related]
8. The use of the l-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines.
Peng XY; Won JH; Rutherford T; Fujii T; Zelterman D; Pizzorno G; Sapi E; Leavitt J; Kacinski B; Crystal R; Schwartz P; Deisseroth A
Cancer Res; 2001 Jun; 61(11):4405-13. PubMed ID: 11389068
[TBL] [Abstract] [Full Text] [Related]
9. Use of l-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells.
Chung I; Schwartz PE; Crystal RG; Pizzorno G; Leavitt J; Deisseroth AB
Cancer Gene Ther; 1999; 6(2):99-106. PubMed ID: 10195877
[TBL] [Abstract] [Full Text] [Related]
